Recurrent Seizures and Serotonin Syndrome Following "2C-I" Ingestion

Journal of Medical Toxicology

Volumn 9, Issue 2, 2013, Pages 196-198

  Bosak, Adam ^a   LoVecchio, Frank ^a   Levine, Michael ^a,b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

2C I; 2CI; Phenethylamine; Rave; Seizure; Serotonin syndrome

Indexed keywords

2,5 DIMETHOXY 4 IODOPHENETHYLAMINE; CYPROHEPTADINE; DESIGNER DRUG; LORAZEPAM; MIDAZOLAM; NALOXONE; PHENETHYLAMINE; PHENOBARBITAL; PROPOFOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CLINICAL EVALUATION; COMA; DISEASE COURSE; EMERGENCY WARD; FOLLOW UP; HUMAN; INGESTION; INHALATION; INTENSIVE CARE UNIT; LABORATORY TEST; MALE; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PATIENT TRANSPORT; RECURRENT DISEASE; RESPIRATORY FAILURE; SEDATION; SEROTONIN SYNDROME; TONIC CLONIC SEIZURE;

ADULT; DESIGNER DRUGS; DIMETHOXYPHENYLETHYLAMINE; EMERGENCY SERVICE, HOSPITAL; HUMANS; INSUFFLATION; MALE; PHENETHYLAMINES; RESPIRATORY INSUFFICIENCY; SEIZURES; SEROTONIN SYNDROME; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878113716     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-013-0287-x     Document Type: Article

References (13)

1. Haroz R, Greenberg MI (2005) Emerging drugs of abuse. Med Clin N Am 89: 1259-76.
2. Andreasen MF, Telving R, Birkler RI et al (2009) A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int 183: 91-6.
3. Theobald DS, Pütz M, Schneider E et al (2006) New designer drug 4-iodo-2, 5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic-mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J Mass Spectrom 41: 872-86.
4. Johnson MP, Mathis CA, Shuligin AT et al (1990) [125I]-2-(2, 5-Dimethoxy-4-iodophenyl)aminoethane ([125]-2C-I) as a label for the 5HT2 receptor in rat frontal cortex. Pharmacol Biochem Behav 35: 211-7.
5. 2C receptors. Br J Pharmacol 136: 510-9.
6. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559: 132-7.
7. Maurer HH (2010) Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit 32: 544-9.
8. Theobald DS, Maurer HH (2007) Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2c-series). Biochem Pharmacol 73: 287-97.
9. Drug Enforcement Administration, Office of Forensic Sciences. Microgram Bulletin. US Department of Justice, Drug Enforcement Administration. 2004; 38: 48-9.
10. DeBoer D, Gijzeles MJ, Bosman IJ et al (1999) More data about the new psychoactive drug 2C-B. J Anal Toxicol 23: 227-8.
11. Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352: 1112-20.
12. Dunkey EJ, Isbister GK, Sibbritt D et al (2003) The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96: 635-42.
13. Kirshner R, Donovan JW (2010) Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med 38: 477-80.